TB Host Directed Therapy

Phase 2 Unknown 200 enrolled The Aurum Institute NPC

RandomizedParallel-groupOpen-labelTreatment

Summary

To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.

Timeline

Start: 2016-11
Primary completion: 2018-09
Completion: 2020-12

Publications

Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, Vangu MDT, Churchyard G. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 Aug;9(8):897-908. doi: 10.1016/S2213-2600(20)30448-3. Epub 2021 Mar 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Auranofin	Small molecule	6 mg	—
Subject	Cholecalciferol	Other / unclassified	—	—
Subject	Dovramilast	Small molecule	—	—
Subject	Everolimus	Small molecule	0.5 mg	—

TB Host Directed Therapy

Summary

Timeline

Publications

Drugs

Indications